Viridian Therapeutics, Inc./DE Restructuring and Related Cost, Expected Number of Positions Eliminated
Viridian Therapeutics, Inc./DE (VRDN) reported Restructuring and Related Cost, Expected Number of Positions Eliminated of 44 position for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-12.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated · last filed 2020-11-12
- Viridian Therapeutics, Inc./DE restructuring and related cost, expected number of positions eliminated for the quarter ending 2020-03-31 was 44.00 position.
- Viridian Therapeutics, Inc./DE restructuring and related cost, expected number of positions eliminated for fiscal 2019 was 44.00 position.
| Period end | Restructuring and Related Cost, Expected Number of Positions Eliminated | Restructuring and Related Cost, Expected Number of Positions Eliminated 3 month | Restructuring and Related Cost, Expected Number of Positions Eliminated 6 month | Restructuring and Related Cost, Expected Number of Positions Eliminated 9 month | Restructuring and Related Cost, Expected Number of Positions Eliminated 12 month |
|---|---|---|---|---|---|
| 2020-09-30 | 44.00 position 10-Q · filed 2020-11-12 | ||||
| 2020-06-30 | 44.00 position 10-Q · filed 2020-08-05 | ||||
| 2020-03-31 | 44.00 position 10-Q · filed 2020-05-08 | ||||
| 2019-12-31 | 44.00 position 10-K · filed 2020-03-13 | ||||
| 2019-08-07 | 26.00 position 10-Q · filed 2019-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |